ARTICLE | Company News
Admune Therapeutics, Novartis deal
October 26, 2015 7:00 AM UTC
Novartis will acquire Admune for an undisclosed sum. Admune’s hetIL-15 is in Phase I testing to treat metastatic cancers. The product is a complex of IL-15 with a cleaved soluble form of the IL-15 re...